DexCom, Inc. (NASDAQ:DXCM) Stock Position Decreased by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,211 shares of the medical device company’s stock after selling 719 shares during the period. Brown Brothers Harriman & Co.’s holdings in DexCom were worth $250,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of DXCM. Townsquare Capital LLC increased its position in shares of DexCom by 43.6% in the third quarter. Townsquare Capital LLC now owns 9,568 shares of the medical device company’s stock worth $641,000 after acquiring an additional 2,905 shares in the last quarter. Freedom Investment Management Inc. grew its position in DexCom by 10.2% during the 3rd quarter. Freedom Investment Management Inc. now owns 3,035 shares of the medical device company’s stock worth $203,000 after purchasing an additional 281 shares in the last quarter. Public Sector Pension Investment Board raised its stake in DexCom by 5.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock valued at $1,196,000 after purchasing an additional 1,000 shares during the period. Captrust Financial Advisors lifted its holdings in shares of DexCom by 4.6% in the third quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock valued at $1,545,000 after purchasing an additional 1,022 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its position in shares of DexCom by 235.0% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 135,323 shares of the medical device company’s stock worth $9,072,000 after buying an additional 94,923 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares of the company’s stock, valued at $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Up 0.8 %

Shares of DXCM opened at $68.29 on Tuesday. The stock’s 50-day moving average price is $82.00 and its 200 day moving average price is $77.12. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $26.69 billion, a price-to-earnings ratio of 47.76, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $141.99.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on DXCM shares. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Finally, Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.